2025
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies
Puzo C, Seropian S, Rinder H, Tormey C, Siddon A. Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies. Bone Marrow Transplantation 2025, 1-3. PMID: 39806028, DOI: 10.1038/s41409-025-02510-8.Peer-Reviewed Original Research
2024
Optimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024, 5: 1236-1242. PMID: 39691272, PMCID: PMC11647727, DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testAssessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis
Musante K, Roome L, Yurtsever N, Rinder H, Tormey C, Lee E. Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis. American Journal Of Clinical Pathology 2024, 162: s147-s147. DOI: 10.1093/ajcp/aqae129.326.Peer-Reviewed Original ResearchSickle cell diseaseRed blood cell unitsSickle cell disease patientsRed blood cellsPatient's HctRBC unitsTransfused RBC unitsRetrospective chart reviewTwo-sample t-testChart reviewAdverse eventsMedian numberPre-procedureProphylactic procedureCell diseasePatientsAcademic hospitalAverage hematocritAverage HctBlood cellsHctTransfusion servicesT-testQuality studiesHematocritThrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs J, Sharma D, Stephens L, Villalba C, Rinder H, Woo J, Wheeler A, Gerberi D, Goel R, Tormey C, Booth G, Bloch E, Adkins B. Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review. British Journal Of Haematology 2024, 204: 1500-1506. PMID: 38291731, DOI: 10.1111/bjh.19313.Peer-Reviewed Original ResearchRisk of thrombosisHemoglobin C traitHemoglobin C diseaseVenous thromboembolismC diseaseIncreased risk of thrombosisProspective cohort studyFactor to thrombosisAssessment of patientsCohort studySystematic reviewInclusion criteriaPregnant individualsThrombotic riskCase seriesCase reportVTE riskChronic haemolysisSystematic literature reviewArterial thrombosisThrombosis riskHigh blood viscosityIncreased riskThrombosisC trait
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test results
2020
Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency
Gupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.Peer-Reviewed Original Research
2015
Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia
Schulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia. Blood 2015, 126: 1385. DOI: 10.1182/blood.v126.23.1385.1385.Peer-Reviewed Original ResearchDe novo acute myeloid leukemiaNovo acute myeloid leukemiaAcute myeloid leukemiaMolecular clonalityAML patientsTumor heterogeneityMyeloid leukemiaNext-generation sequencingNormal-risk subjectsAdverse prognostic indicatorTime of diagnosisFurther prospective studiesLong-term outcomesFLT3-ITD mutationHigh-risk groupChoice of therapyFirst prospective evidenceLimited clinical utilityHigh-risk classificationEarly survivalStudy patientsOverall survivalPatient agePatient subsetsInitial diagnosis
2012
Normalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply